ESPR — Esperion Therapeutics Balance Sheet
0.000.00%
- $638.41m
- $850.57m
- $332.31m
- 10
- 49
- 95
- 51
Annual balance sheet for Esperion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 305 | 259 | 167 | 82.2 | 145 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 22.9 | 33.7 | 48.5 | 80.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 346 | 329 | 247 | 201 | 338 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7.31 | 2.56 | 1.2 | 4.67 | 5.77 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 353 | 382 | 248 | 206 | 344 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 94.1 | 73.4 | 92.3 | 156 | 246 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 449 | 579 | 572 | 661 | 733 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -96.1 | -197 | -324 | -455 | -389 |
| Total Liabilities & Shareholders' Equity | 353 | 382 | 248 | 206 | 344 |
| Total Common Shares Outstanding |